Can cannabis stop Parkinson's hallucinations?
A pioneering clinical trial will investigate if cannabidiol (CBD) – a compound found in the cannabis plant – can treat hallucinations and delusions in people living with Parkinson’s.
Promising results from a phase II study for people with early-stage Parkinson’s
A phase II clinical trial of tavapadon, a drug developed by Cerevel Therapeutics, has shown improvements in movement symptoms. The results have been announced on the company website.
New guide to help charities and patients work with drug companies
A new guide has been launched to help charities support patients to have their say on research carried out by the pharmaceutical industry.
Tickets for our national research conference are on sale
This event, for anyone with an interest in Parkinson’s research, will take place on Saturday 23 November at the Cranmore Park Conference & Events Centre, outside Birmingham.
Research shows at home exercise improves movement symptoms
Researchers have shown that those taking part in a home-based exercise programme experienced improvements in their motor symptoms.
Prostate drug shows promise in Parkinson’s
A drug used to treat enlarged prostates may have exciting potential for slowing down Parkinson's, according to research published in the Journal of Clinical Investigation.
Scientists uncover further evidence that Parkinson's could start in the gut
New research in rats has shown that alpha-synuclein, an abnormal protein normally found in brain cells affected in Parkinson's, can move rapidly from the gut to the brain. These findings support growing evidence that Parkinson’s may start in the gut rather than the brain.
Hormone treatment slows Parkinson's symptoms in mice
Researchers have shown that boosting levels of oestrogen in the brains of mice improved symptoms by slowing the build-up of the toxic protein alpha-synuclein.
United in the search for better treatments
The Critical Path for Parkinson's meeting brought together pharmaceutical companies, universities, charities and regulatory bodies to address barriers to new treatments.